Indol-3-ylcycloalkyl ketones: Effects of N1 substituted indole side chain variations on CB2 cannabinoid receptor activity

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 295-315

  Frost, Jennifer M ^a   Dart, Michael J ^a   Tietje, Karin R ^a   Garrison, Tiffany R ^a   Grayson, George K ^a   Daza, Anthony V ^a   El Kouhen, Odile F ^a   Yao, Betty B ^a   Hsieh, Gin C ^a   Pai, Madhavi ^a   Zhu, Chang Z ^a   Chandran, Prasant ^a   Meyer, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [3 (2,2,3,3 TETRAMETHYLCYCLOPROPANECARBONYL) 1H INDOL 1 YL]ETHYL]OXAZOLIDIN 2 ONE; [1 (4 HYDROXYBUTYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; CANNABINOID 2 RECEPTOR; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HUMAN CELL;

DRUG DESIGN; HUMANS; INDOLES; KETONES; LIGANDS; MOLECULAR STRUCTURE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74849084874     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901214q     Document Type: Article

References (59)

1. (a) Cabral, G. A.; Marciano-Cabral, F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukocyte Biol. 2005, 78, 1192-1197.
2. (b) Van Sickle, M. D.; Duncan, M.; Kingsley, P. J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J. S.; Marnett, L. J.; Marzo, V. D.; Pittman, Q. J.; Patel, K. D.; Sharkey, K. A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310, 329-332.
3. (c) Beltramo, M.; Bernardini, N.; Bertorelli, R.; Campanella, M.; Nicolussi, E.; Fredduzzi, S.; Reggiani, A. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 2006, 23, 1530-1538.
4. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
5. Chapman, V.; Finn, D. P. Analgesic effects of cannabinoids: sites and mechanisms of action. Rev. Analg. 2003, 7, 25-39.
6. (a) Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R. G.; Ross, R. A.; Mechoulam, R.; Fride, E. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14228-14233.
7. 2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol. 2003, 3, 62-67.
8. 2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002, 96, 253-260.
9. 2 cannabinoid receptors. Anesthesiology 2003, 99, 955-960.
10. (a) Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R. G.; Ross, R. A.; Mechoulam, R.; Fride, E. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14228-14233.
11. 2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol. 2003, 3, 62-67.
12. 2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002, 96, 253-260.
13. 2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J. Med. Chem. 2007, 50, 3851-3856.
14. (b) Kunos, G.; Osei-Hyiaman, D.; Bátkai, S.; Sharkey, K. A.; Makriyannis, A. Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol. Sci. 2008, 30, 1-7.
15. 2 receptors as new therapeutic targets for liver diseases. Br. J. Pharmacol. 2008, 153, 286-289.
16. 2 in the liver. Gastroenterology 2005, 128, 742-755.
17. (c) Bátkai, S.; Osei-Hyiaman, Pan, H.; el-Assal, O.; Rajesh, M.; Mukhopadhyoy, P.; Hong, F.; Harvey-White, J.; Jafri, A.; Haskó, G.; Huffman, J. W.; Gao, B.; Kunos, G.; Pacher, P. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 2007, 21, 1788-1800.
18. (a) Idris, A. I; Sophocleous, A.; Landao-Bassonga, E.; van't Hof, R. J; Ralston, S. H. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 2008, 149, 5619-5626.
19. 2, regulates bone mass. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 696-701.
20. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 2003, 23, 11136-11141.
21. (a) Shi, Y.; Zou, M.; Baitei, E. Y.; Alzahrani, A. S.; Parhar, R. S.; Al-Makhalafi, Z.; Al-Mohanna, F. A. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther. 2008, 15, 101-107.
22. (b) Flygar, J.; Gustafsson, K.; Kimby, E.; Christensson, B.; Sander, B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantel cell lymphoma. FEBS Lett. 2005, 579, 6885-6889.
23. 2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett. 2005, 579, 5084-5088.
24. (a) Docagne, F.; Mestre, L.; Loria, F.; Hernangomez, M.; Correa, F.; Guaza, C. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin. Ther. Targets 2008, 12, 185-195.
25. (b) Pryce, G.; Baker, D. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci. 2005, 28, 272-276.
26. 2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 2007, 27, 2396-2402.
27. (d) Baker, D.; Pryce, G.; Croxford, J. L.; Brown, P.; Pertwee, R. G.; Huffman, J.W.; Layward, L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404, 84-87.
28. 2 receptors in glucose homeostasis in rats. Eur. J. Pharmacol. 2007, 565, 207-211.
29. D'Ambra, T. E.; Estep, K. G.; Bell, M. A.; Eissenstat, M. A.; Josef, K. A.; Ward, S. J.; Haycock, D. A.; Baizman, E. R.; Casiano, F. M.; Beglin, N. C.; Chippari, S. M.; Grego, J. D.; Kullnig, R. K.; Daley, G. T. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J. Med. Chem. 1992, 35, 124-135.
30. (a) Huffman, J. W.; Dai, D.; Martin, B. R.; Compton, D. R. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 1994, 4, 563-566.
31. (b) Huffman, J. W.; Zengin, G.; Wu, M.-J.; Lu, J.; Hynd, G.; Bushell, K.; Thompson, A. L. S.; Bushell, S.; Tartal, C.; Hurst, D. P.; Reggio, P. H.; Selley, D. E.; Cassidy, M. P.; Wiley, J. L.; Martin, B. R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg. Med. Chem. 2005, 13, 89-112.
32. (a) Gallant, M.; Dufresne, C.; Gareau, Y.; Guay, D.; Leblanc, Y.; Prasit, P.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Metters, K. M.; Labelle, M. New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg. Med. Chem. Lett. 1996, 9, 2263-2268.
33. (b) Gallant, M.; Gareau,Y.; Guay, D.; Labelle, M.; Prasit, P. U.S. Patent 5,532,237, 1996.
34. (c) Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulet, J. M.; Gottshall, S. L.; Mark, L.; Pearson, M. S.; Miller,W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Elsemore, D. A.; Toth, M.; Koetzner, L.; Whiteside, G. T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005, 48, 658-672.
35. (a) Hynes, J., Jr.; Leftheris, K.; Wu, H.; Pandit, C.; Chen, P.; Norris, D. J.; Chen, B.-C.; Zhao, R.; Kiener, P. A.; Chen, X.; Turk, L. A.; Patil-Koota, V.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W. C-3 Amido-indole cannabinoid receptor modulators. Bioorg. Med. Chem. Lett. 2002, 12, 2399-2402.
36. (b) Leftheris, K.; Zhao, R.; Chen, B.-C.; Kiener, P.;Wu, H.; Pandit, C. R.;Wrobleski, S.; Chen, P.; Hynes, J., Jr.; Longphre, M.; Norris, D. J.; Spergel, S.; Tokarski, J. U.S. Patent 6,653,304, 2003.
37. Wrobleski, S.; Chen, P.; Hynes, J., Jr.; Lin, S.; Norris, D. J.; Pandit, C. R.; Spergel, S.; Wu, H.; Tokarski, J.; Chen, X.; Gillooly, K. M.; Kiener, P. A.; McIntyre, K. W.; Patil-koota, V.; Shuster, D. J.; Turk, L. A.; Yang, G.; Leftheris, K. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J. Med. Chem. 2003, 46, 2110-2116.
38. Ratcliffe, P. D.; Adam-Worrall, J.; Morrison, A. J.; Francis, S. J.; Kiyoi, T. Patent Application WO2007/023143, 2007.
39. Bleicher, K.; Nettekoven, M. H.; Pflieger, P.; Roever, S. U.S. Patent Application 2006/0089367, 2006.
40. (a) Eatheron, A. J.; Giblin, G. M. P.; Johnson, M. R.; Mitchell, W. L.; Perboni, A.; Slingsby, B. P. Patent Application WO05/121140, 2005.
41. (b) Eatheron, A. J.; Giblin, G. M. P.; Jandu, K. S.; Johnson, M. R.; Mitchell, W. L.; Naylor, A.; Sweeting, J. A. Patent Application WO07/017264, 2007.
42. Barth, F.; Guillaumont, C.; Rinaldi-Carmona, M.; Vernhet, C. U.S. Patent 7,138,424, 2006.
43. Shankar, B. B.; Gilbert, E.; Rizvi, R. K.; Huang, C.; Kozlowski, J. A.; McCombie, S.; Shih, N. Y. Patent Application WO06/002133, 2006.
44. 2 cannabinoid receptor activity. J. Med. Chem. 2008, 51, 1904-1912.
45. Eissenstat, M. A.; Bell, M. R; D'Ambra, T. E.; John, A. E.; Daum, S. J.; Ackerman, J. H.; Gruett, M. D.; Kumar, V.; Estep, K. G.; Olefirowicz, E. M.; Wetzel, J. R.; Alexander, M. D.; Weaver, J. D., III; Haycock, D. A.; Luttinger, D. A.; Casiano, F. M; Chippari, S. M.; Kuster, J. E.; Stevenson, J. I.; Ward, S. J. Aminoalkylindoles: Structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. 1995, 38, 3094-3105.
46. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001, 93, 239-245.
47. (b) Ibrahim, M.; Deng, H.; Zvonok, A.; Cockayne, D. A.; Kwan, J.; Mata, H.; Vanderah, T. W.; Lai, J.; Porreca, F.; Makriyannis, A.; Malan, T. P. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10529-10533.
48. (c) Makriyannis, A.; Deng, H. U.S. Patent 7,173,027, 2007.
49. Malan, T. P., Jr; Ibrahim, M. M.; Deng, H.; Liu, Q.; Mata, H. P.; Vanderah, T.; Porreca, F.; Makriyannis, A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001, 93, 239-245.
50. Ibrahim, M. M.; Porreca, F.; Lai, J.; Albrecht, P. J.; Rice, F. L.; Khodorova, A.; Davar, G.; Makriyannis, A.; Vanderah, T. W.; Mata, H. P.; Malan, T. P., Jr. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opiods. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3093-3098.
51. 2-selective agonist, GW405833. Eur. J. Pharmacol. 2005, 528, 65-72.
52. Yao, B. B.; Mukherjee, S.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Hooker, B. A.; Dart, M. J.; Sullivan, J. P.; Meyer, M. D. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br. J. Pharmacol. 2006, 149, 145-154.
53. 2) selective ligand AM1241 and it's resolved enantiomers. Br. J. Pharmacol. 2007, 151, 1061-1070.
54. Bell, M. R. 3-Carboxy-1-amino-1H-indoles as useful analgesics. EP171037, 1986.
55. Bergman, J.; Venemalm, L. Acylation of the zinc salt of indole. Tetrahedron 1990, 46, 6061-6066.
56. 4 (CP-55,940) is (-)-cis-3-[2-hydroxy-4-(1,1- dimethylheptyl)-phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol and was obtained from Tocris Bioscience.
57. 2 cannabinoid receptors. Eur. J. Pharmacol. 2004, 505, 1-9.
58. Yao, B. B.; Hsieh, G. C.; Frost, J. M.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Zhu, C. Z.; Pai, M.; Chandran, P.; Salyers, A. K.; Wensink, E. J.; Honore, P.; Sullivan, J. P.; Dart, M. J.; Meyer, M. D. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br. J. Pharmacol. 2008, 153, 390-401.
59. Partch, R.; Brewster, W.; Stokes, B. 2-Oxaadamantane-1-N,N,N-trimethylmethanaminium iodide: synthesis and potential for muscarinic activity. Croat. Chem. Acta 1985, 58, 661-669.